ATP128 Clinical Therapeutic Cancer Vaccine Activates NF-κB and IRF3 Pathways through TLR4 and TLR2 in Human Monocytes and Dendritic Cells
Roberta Pascolutti, Lakshmi Yeturu, Géraldine Philippin, Stéphane Costa Borges, Magali Dejob, Marie-Laure Santiago-Raber* and Madiha Derouazi*
Cancers 2022, 14, 5134

Heterologous Prime-Boost Vaccination with a Peptide-Based Vaccine and Viral Vector Reshapes Dendritic Cell, CD4+ and CD8+ T Cell Phenotypes to Improve the Antitumor Therapeutic Effect
Tamara Hofer, Matteo Rossi, Susanna Carboni, Wilma Di Berardino Besson, Dorothee von Laer, Guido Wollmann, Madiha Derouazi, and Marie-Laure Santiago-Raber
Cancers 2021, 13(23), 6107

A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity
Krishna Das, Elodie Belnoue, Matteo Rossi, Tamara Hofer, Sarah Danklmaier, Tobias Nolden, Liesa-Marie Schreiber, Katharina Angerer, Janine Kimpel, Sandra Hoegler, Bart Spiesschaert, Lukas Kenner, Dorothee von Laer, Knut Elbers, Madiha Derouazi & Guido Wollmann
Nat Commun 12, 5195 (2021)

STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity
Matteo Rossi, Susanna Carboni, Wilma Di Berardino-Besson, Erika Riva, Marie-Laure Santiago-Raber, Elodie Belnoue and Madiha Derouazi
Front. Immunol. 12:695056 (2021)

Novel Protein-Based Vaccine Against Self-Antigen Reduces the Formation of Sporadic Colon Adenomas in Mice
Elodie Belnoue, Alyssa A. Leystra, Susanna Carboni, Harry S. Cooper, Rodrigo T. Macedo, Kristen N. Harvey, Kimberly B. Colby, Kerry S. Campbell, Lisa A. Vanderveer, Margie L. Clapper and Madiha Derouazi
Cancers 2021, 13, 845

Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine
Belnoue E, Mayol JF, Carboni S, Di Berardino Besson W, Dupuychaffray E, Nelde A, Stevanovic S, Santiago-Raber ML, Walker PR, Derouazi M.
JCI Insight. 2019 Apr;4(11):e127305

Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines
Grau M, Walker PR, Derouazi M
Cell Mol Life Sci. 2018 Mar;75(16): 2887-2896

Enhancing anti-tumor immune responses by optimized combinations of cell-penetrating peptide based-vaccines and adjuvants
Belnoue E, Di Berardino-Besson W, Gaertner H, Carboni S, Dunand-Sauthier I, Cerini F, Suso-Inderberg EM, Wälchli S, König S, Salazar AM, Hartley O, Dietrich PY, Walker PR and Derouazi M.
Mol Ther. 2016 Sep;24(9):1675-85

Cell-penetrating peptides – the Swiss Army knife of cancer vaccines
Walker PR, Belnoue E, Dietrich PY, Derouazi M.
Oncoimmunology. 2016 Mar; 5(3): e1095435

Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity
Derouazi M, Di Berardino-Besson W, Belnoue E, Hoepner S, Walther R, Benkhoucha M, Teta P, Dufour Y, Yacoub Maroun C, Salazar AM, Martinvalet D, Dietrich PY, Walker PR.
Cancer Res. 2015 Aug 1;75(15):3020-31

Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours
Hoepner S, Loh JM, Riccadonna C, Derouazi M, Maroun CY, Dietrich PY, Walker PR.
PLoS One. 2013 May 23;8(5):e63933

Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development
Tran Thang NN, Derouazi M, Philippin G, Arcidiaco S, Di Berardino-Besson W, Masson F, Hoepner S, Riccadonna C, Burkhardt K, Guha A, Dietrich PY, Walker PR.
Cancer Res. 2010 Jun 15;70(12):4829-39

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL: